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Abstract 
Calcium minerals such as hydroxyapatite (HAp) can be detected non-invasively in vivo using 
nuclear imaging agents such as [18F]NaF (available from cyclotrons), for positron emission 
tomography (PET) and 99mTc-radiolabelled bisphosphonates (BP; available from 99mTc 
generators for single photon emission computed tomography (SPECT) or scintigraphy). These 
two types of imaging agents allow detection of bone metastases (based on the presence of HAp) 
and vascular calcification lesions (that contain HAp and other calcium minerals). With the aim 
of developing a cyclotron-independent PET radiotracer for these lesions, with broad calcium 
mineral affinity and simple one-step radiolabelling, we developed [68Ga]Ga-THP-Pam. 
Radiolabelling with 68Ga is achieved using a mild single-step kit (5 min, room temperature, pH 
7) to high radiochemical yield and purity (>95%). NMR studies demonstrate that Ga binds via 
the THP chelator, leaving the BP free to bind to its biological target. [68Ga]Ga-THP-Pam shows 
high stability in human serum. The calcium mineral binding of [68Ga]Ga-THP-Pam was 
compared in vitro to two other 68Ga-BPs which have been successfully evaluated in humans, 
[68Ga]Ga-NO2APBP and [68Ga]Ga-BPAMD, as well as [18F]NaF. Interestingly, we found that 
all 68Ga-BPs have a high affinity for a broad range of calcium minerals implicated in vascular 
calcification disease, while [18F]NaF is selective for HAp. Using healthy young mice as a 
model of metabolically active growing calcium mineral in vivo, we compared the 
pharmacokinetics and biodistribution of [68Ga]Ga-THP-Pam with [18F]NaF as well as 
[68Ga]NO2APBP. These studies revealed that [68Ga]Ga-THP-Pam has high in vivo affinity for 
bone tissue (high bone/muscle and bone/blood ratios) and fast blood clearance (t1/2 <10 min) 
comparable to both [68Ga]NO2APBP and [18F]NaF. Overall, [68Ga]Ga-THP-Pam shows high 
potential for clinical translation as a cyclotron-independent calcium mineral PET radiotracer, 
with simple and efficient radiochemistry that can be easily implemented in any radiopharmacy.  
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Introduction 
Calcium is an essential element in human biology and the most abundant metallic 
element in the body by weight.1,2 The majority of body calcium is in the form of a solid mineral, 
hydroxyapatite (HAp; Ca5(PO4)3(OH)) in bones.3 This calcium mineral can be targeted in vivo 
using bisphosphonates (BPs, Scheme 1A), which led to the development of BP-based 
radiotracers such as [99mTc]Tc-methylene diphosphonate (MDP) (99mTc; t1/2 = 6.02 h). 
Introduced half a century ago, [99mTc]Tc-MDP is still widely used in nuclear medicine to image 
bone disease, particularly metastatic cancer in the bones using single photon emission 
computed tomography (SPECT) imaging (Scheme 1A).4-7 Its chemical structure, however, 
remains unknown.8 
In recent years there has been increasing interest in performing bone scans using 
positron emission tomography (PET) imaging. This is due to its better sensitivity and spatial 
resolution, compared to SPECT, which allows the detection of smaller lesions as well as 
improved image quantification. The radiotracer of choice in clinical PET imaging of bone 
lesions is the sodium salt of [18F]fluoride (18F; t1/2 = 110 min; β+ = 97%).9-11 Interestingly, 
[18F]NaF binds HAp not by interacting with calcium but by displacement of the hydroxide in 
the HAp lattice (Scheme 1A).12 
 
 
Scheme 1. (A) Schematic showing the proposed binding of bisphosphonate (BP)-based imaging agents and 
[18F]NaF to hydroxyapatite (HAp); (B) Formulae of the different calcium salts discussed in this work. 
 
 
Besides HAp, other calcium minerals are implicated in a number of health conditions 
in which a sensitive, non-invasive imaging method such as PET would be of great use. One 
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such example is vascular calcification, a clinical marker of atherosclerosis in which soft 
vascular tissue forms plaques that can occlude the flow of blood through the affected vessel 
and can rupture, causing potentially fatal downstream effects.13 Atherosclerosis can lead to 
cardiovascular disease (CVD), the leading cause of death globally with ca. 18 million deaths 
in 2016 and an upward trend expected over the next decade.14 The primary composition of 
vascular calcification lesions is disputed in the literature, with not only HAp, but also calcium 
oxalate monohydrate, and β-tricalcium phosphate partially substituted with magnesium 
(whitlockite) being reported as the main components.15-20 Other calcium minerals such as 
calcium carbonate, calcium pyrophosphate and amorphous calcium phosphate have also been 
reported, as well as heterogeneous composition between patients.15,18,21 Thus, it seems that 
calcium in these lesions is present as a mixture that may contain several non-HAp materials, 
summarised in Scheme 1B. The role that these non-HAp calcium minerals may have in 
different stages of CVD, and their potential as imaging biomarkers, remain to be elucidated.  
Despite the advantages of [18F]NaF as a PET radiotracer, its binding mechanism and in 
vitro/vivo data indicate that its target in vivo is HAp (Scheme 1A) and not other calcium 
minerals that have also been identified in vascular calcification lesions.22,23 BPs on the other 
hand are not selective for HAp, showing broader calcium mineral affinity.24,25 Hence, there is 
considerable interest in the development of BP-based PET radiotracers. These should allow the 
detection of bone lesions, as recently demonstrated in patients,5,26-30 but also calcified 
vasculature which we have discussed above may contain different types of calcium minerals 
besides HAp and thus may benefit from the broader calcium mineral affinity of BPs.  
From the radiopharmacy and clinical translation perspective, a disadvantage of current 
BP-based PET radiotracers is a relatively complex radiochemistry. 18F is produced by 
cyclotrons, which are expensive and complex instruments, but can produce [18F]NaF in large 
quantities without any further need for complicated radiosynthetic procedures.10 On the other 
hand, PET BPs rely on the use of radiometals and hence are bifunctional chelators that 
generally involve multi-step syntheses and radiosynthetic procedures, which may require an 
automated synthesis module for clinical translation.5,26-28,31-40 The most promising radionuclide 
in the development of PET BPs is 68Ga (t1/2 = 68 min; β+ = 89%). This radiometal not only 
benefits from a short radiation decay half-life that minimises radiation dose to patients, but also 
availability from both cyclotrons and benchtop generators that can be installed in any 
radiopharmacy, allowing cyclotron-independent PET radiotracers on-site.41 Having a variety 
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of such cyclotron-independent radiotracers is attractive as it would not only provide an 
alternative supply of some PET radiotracers in case of cyclotron failures, but also potentially 
open the door to cyclotron-independent PET scanners, widening access to PET for patients 
geographically distant from cyclotron centres. Notable examples of 68Ga radiotracers that are 
increasingly being exploited for clinical PET today include those based on PSMA for imaging 
prostate cancer,42-44 octreotide analogues for neuroendocrine tumours,45 and recently FAP 
inhibitors, which shows exciting prospects as a pan-cancer PET imaging agent.46 
We set out to create a BP-based “cold kit” radiopharmaceutical for PET imaging of 
calcium minerals, in which 68Ga generator eluate could be added directly to a vial containing 
pre-formulated reagents and used without any further steps. Our motivation was not only to 
explore the broad calcium mineral affinity of BPs, but also to combine the superior 
performance of PET imaging with the simplicity of radionuclide generator kit-based synthesis 
and availability, that has been largely responsible for the long-term success of 99mTc 
radiochemistry and the nuclear imaging field. Here, we describe the development of [68Ga]Ga-
THP-Pam, a 68Ga complex of the efficient gallium chelator (tris)hydroxypyridinone (THP),44, 
47-57 conjugated with the clinically used BP pamidronate (Pam) (Figure 1A) and its comparison 
with [18F]NaF and two other 68Ga-labelled BPs—BPAMD (Figure 1B) and NO2APBP (Figure 
1C)—which have undergone extensive evaluation including first in human studies.5, 26-28, 31-33, 
58 
  
Figure 1. Chemical structures of the bifunctional bisphosphonate chelators discussed in this work. (A) THP-Pam; 
(B) BPAMD; (C) NO2APBP.  
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Results and discussion 
Synthesis of THP-Pam. The bifunctional chelator THP-Pam was designed to include a 
(tris)hydroxypyridinone group for efficient gallium chelation, as well as the bone-targeting 
moiety pamidronate (Pam), a clinically-used aminobisphosphonate with known high affinity 
for bone mineral.59 Pamidronate was synthesised according to a literature procedure (Scheme 
2A),60 leading to a pure white solid with a shelf-life at room temperature of at least 4485 
days, as measured by NMR, MS and elemental analysis. Among the clinically used second 
generation amino-BPs, pamidronate has the shorter chain between the BP and the amine 
groups, keeping the overall size of the molecule as small as possible, which generally leads to 
faster pharmacokinetics (PK).  
In order to form the conjugate, the primary amine group of pamidronate was reacted 
with THP-isothiocyanate50 in a single step (Scheme 2B). Water was chosen as the solvent for 
this reaction due to the poor solubility of amino-BPs in organic solvents.24 This however 
opened the possibility of the slow degradation of the isothiocyanate in water. To increase the 
speed of reaction and reduce the likelihood of degradation, a minimal volume of solvent was 
used and the reaction was performed at 90°C in a sealed vial with a large excess of pamidronate 
to help drive the desired reaction. Triethylamine was used to achieve a reaction pH of ~11 in 
order to deprotonate the amine of pamidronate (pKa = 10.40–13.06),61 and allow the reaction 
to proceed. The high pH increased the water solubility of both pamidronate and THP-NCS. 
Monitoring the progress of the reaction by LC/MS indicated that 2 h was the optimal reaction 
time. These reaction conditions were successful in reducing the number of by-products; the 
only products observed by LC/MS, aside from excess pamidronate, were >90% THP-Pam (m/z 
[M + 2H]2+ = 598) and <10 % THP-NCS hydrolysed to a primary amine (m/z [M + 2H]2+ = 
460).  
The resulting thiourea bond has been reported to be less stable than amide bonds,62,63 
however thiourea bonds have also been shown to be stable in vivo over timescales of up to 24 
h.64 Due to the short circulation time of BPs and short half-life of 68Ga, the risk of hydrolysis 
of the thiourea bond during imaging was considered to be minimal. An amide bond formation 
would have been an alternative bioconjugation strategy, using N-hydroxysuccinimide esters. 
However, the relatively fast hydrolysis of the activated esters would have made water an 
unsuitable solvent for the required bioconjugation conditions (high pH and T) and the 
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commercial availability of THP-isothiocyanate allowed for a more straightforward synthetic 
approach. 
 
Scheme 2. Synthesis of THP-Pam. (A) Synthesis of the amino-BP pamidronate; (B) Thiourea bond formation 
between pamidronate and THP-NCS yields THP-Pam in 71% yield. 
To remove the unreacted pamidronate, the reaction solution was loaded onto a Sep-Pak 
tC18 cartridge, from which pamidronate could selectively be eluted in water (0.1% TFA), while 
the other products were subsequently eluted in 1:1 water:acetonitrile (0.1% TFA). Collecting 
small volume fractions, those with the most THP-Pam and least hydrolysed THP-NCS, as 
measured using LC/MS, were collected. LC/MS analysis of the collated fractions confirmed 
the success of this purification step, with a final purity of >95% THP-Pam. After evaporation, 
THP-Pam was obtained as a white powder in 71% yield and no further attempts were made to 
optimise reaction conditions. The product can also be purified by semi-preparative HPLC 
(HPLC method 1 (Table S1); tR = 20.9 min).  
Characterisation of THP-Pam. Analytical C18 reverse-phase HPLC analysis showed a single 
peak (Figure 2A) with some tailing, indicating a pure product with multiple ionisation states or 
different modes of retention on the stationary phase, as previously seen for other BP 
compounds.24,31,32,38 THP-Pam eluted at tR =10.4 minutes (HPLC method 2 (Table S2)), at 
which point the mobile phase is ~70% water, as confirmed by LC/MS analysis (Figure 2B). 
Pamidronate, on the other hand, elutes at tR = 1.7 minutes under the same conditions. After 
purification, LC/MS analyses occasionally indicated the presence of THP-Pam + Fe (m/z [M + 
2H]2+ = 625). This highlights the tendency for both THP and BPs to bind to metals ions, 
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especially iron(III),54,65-67 and the importance of avoiding metal contamination at any stage of 
reaction. Upon binding to iron, THP-Pam changes from a white powder to a pink or red powder, 
providing an extremely sensitive indicator of the presence of iron.55 As this was not the case 
with our purified product, it was assumed that the iron was bound during transition through the 
LC/MS system and was not present in the product. 
The 31P{1H} NMR spectrum of THP-Pam showed a single peak at 17.86 ppm, and 
consistent with the chemical shift for a BP (Figure 2C). The 1H NMR spectrum also showed 
the expected resonances for THP-Pam, however all peaks were rather broad (Figure 2D). This 
is likely due to different ionisation states of the molecule causing different conformations or 
small degrees of iron binding from solvent impurities. 19F NMR revealed the presence of TFA 
salts in the final product (Figure 2E), even after low-vacuum evaporation. This was further 
confirmed by elemental analysis and is due to the presence of TFA in the mobile phases used 
during purification of THP-Pam. 
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Figure 2. Characterisation of THP-Pam. (A) Reverse-phase C18 HPLC UV (254 nm); (B) ESI-MS spectrum (+ve 
mode) from LC/MS; (C) 31P{1H} NMR in D2O; (D) 1H NMR in D2O; (E) 19F NMR in D2O confirming the 
presence of TFA salts. 
As both pamidronate and THP are known metal chelators,49,68 we conducted NMR 
studies in order to determine whether gallium will preferentially bind to THP, as expected due 
to its high affinity towards this metal, or if the BP could be involved. This is an important factor 
as competing of the BP with the chelator for the binding of gallium-68 has been noted in 
previous BP-based tracers.32,36 To investigate this possibility, an aqueous solution (D2O) of 
THP-Pam of known concentration and adjusted to pH 9 by addition of Na2CO3 was prepared 
at room temperature. To this solution, known amounts of non-radioactive gallium nitrate were 
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added incrementally and the binding process monitored by 31P{1H} NMR to monitor the BP 
moiety, and the aromatic region of the 1H NMR spectrum to monitor the hydroxypyridinone 
moieties responsible for the chelating properties of THP (Figure 3). As Ga(III) ions were added, 
a loss of symmetry and a change in chemical shift was observed in the aromatic region of the 
1H NMR spectrum (Figure 3A), indicating a change in the chemical environment of the 
hydroxypyridinone arms of THP and hence supportive of direct metal binding, as seen in 
previous THP studies.69 Meanwhile the bisphosphonate peak in the 31P{1H} NMR spectrum 
(Figure 3B) did not change, apart from minor peak broadening likely caused by slowing of the 
movement of the THP arms in response to metal binding, and a minor chemical shift from 
17.90 to 17.97 ppm as gallium was added. As a control, gallium nitrate was added to a solution 
of pamidronate under the same conditions and monitored by 31P{1H} NMR and, as expected, 
a distinct loss of symmetry and homogeneity was observed upon addition of gallium to the 
solution, with several new species with chemical shifts in the range of 22.4–3.0 ppm being 
formed (Figure 3C). Altogether, these data indicate that THP-Pam—at equimolar and sub-
equimolar concentrations of gallium—will bind gallium in the THP chelator, and not the BP. 
 
 
Figure 3. NMR titration experiments (D2O and pH 9) of THP-Pam and pamidronate upon [natGa]gallium nitrate 
addition demonstrating the lack of involvement of the bisphosphonate of THP-Pam in gallium binding. Each 
spectrum is scaled according to the largest peak shown for the sake of clarity. (A) 1H NMR 4.0–7.8 ppm window 
showing aromatic protons of THP-Pam corresponding to hydroxypyridinone arms, which show changes in 
chemical shift and loss of symmetry upon gallium binding, indicating a change in chemical environment; (B) 
31P{1H} NMR showing that BP phosphorus atoms exhibit no chemical shift or loss of symmetry or homogeneity 
upon gallium binding, consistent with lack of involvement; (C) 31P{1H} NMR showing pamidronate binding to 
gallium for comparative purposes, which shows a clear loss of symmetry and homogeneity upon gallium binding. 
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Radiochemistry. Having established that when reacting THP-Pam with gallium the metal ion 
binds to the THP chelator, and not the BP group, the radiolabelling reaction with 68Ga was 
evaluated. It was found that 68Ga radiolabelling is fast and efficient. In a typical reaction, a 250 
μL aliquot of gallium-68 eluted from an Eckert and Ziegler 68Ge/68Ga generator in 0.1 M HCl 
was added to 4.18 nmol THP-Pam in water (5 μg) and neutralised with an aqueous 1 M solution 
of sodium bicarbonate. Both stock solutions were prepared using Chelex-treated water to 
minimise the presence of iron(III). After incubating the reaction for 5 min at room temperature, 
radio-ITLC and radio-HPLC indicated quantitative (>97%) complexation of 68Ga (vide infra, 
Figure 4). We measured non-optimised molar activities up to 17.3 MBq nmol-1. In order to 
simplify this further to a pre-prepared kit, it is possible to freeze-dry the THP-Pam and sodium 
bicarbonate prior to reaction and elute the generator directly into a vial containing the dried 
reactants, scaling quantities as required. This opens up the possibility of GMP kit-based 
production of THP-Pam by simple addition of 68Ga generator eluate into a sealed vial. 
Radio-ITLC was performed using glass microfibre chromatography paper (ITLC) 
impregnated with silicic acid in order to retain [68Ga]Ga-THP-Pam as well as possible. By 
developing the ITLC paper in 0.5 M citrate buffer, unbound 68Ga moved with the solvent front, 
giving a clear distinction between [68Ga]Ga-THP-Pam on the baseline (Figure 4A). This is in 
contrast to unbound 68Ga, which primarily moves with the solvent front (Figure 4C). Radio-
HPLC (C18-RP) was performed under the same conditions as analytical HPLC (method 2 
(Table S2)). [68Ga]Ga-THP-Pam eluted as a single peak with a retention time that is 
approximately 30 seconds later compared to THP-Pam, consistent with the expectation that the 
binding of the metal to the hydroxyl and ketone groups of THP leads to a small increase in 
lipophilicity and hence a slightly longer retention on reverse-phase HPLC (Figure 4B). Figure 
4C–D shows the ITLC and radio-HPLC chromatograms of neutralised [68Ga]GaCl3 for 
comparison. Measurement of logP in water/octanol (-2.69 ± 0.03) and logD7.4 in PBS/octanol 
(-2.72 ± 0.07) showed that [68Ga]Ga-THP-Pam was highly hydrophilic as expected for a BP, 
as well as existing gallium-68 labelled conjugates of THP.44 
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Figure 4. Radioanalysis of [68Ga]Ga-THP-Pam and unbound 68Ga as a comparison. (A) ITLC of [68Ga]Ga-THP-
Pam in 0.5 M citrate buffer pH 5.5. (B) Reverse-phase C18 radio-HPLC of [68Ga]Ga-THP-Pam. (C) ITLC of 
unbound 68Ga, showing migration to the solvent front other than colloidal 68Ga. (D) Reverse-phase C18 radio-
HPLC of unchelated 68Ga. 
 
The different radiochemical labelling conditions and purification steps required for the 
in vivo use of the different PET radiotracers discussed in this work (68Ga-BPs and [18F]NaF) 
have been outlined in Table 1. [18F]NaF is received directly from the cyclotron and no 
radiochemistry is necessary, apart from two ion exchange cartridges prior to injection into 
patients.10 The radiolabelling processes of [68Ga]Ga-BPAMD and [68Ga]NO2APBP take 
advantage of the well-established radiochemistry associated with their chelators. In both cases, 
heating to 95°C is required for radiolabelling.31,32 Heating is a requirement for NO2APBP 
radiolabelling, despite the similarity between this chelator and NOTA, which can be labelled 
at room temperature.70 In NO2APBP, however, the presence of the phosphonates allows the 
formation of an out-of-cage complex and so [68Ga]Ga-NO2APBP cannot be prepared at room 
temperature.32 The generator eluate may be processed prior to labelling of NO2APBP to allow 
milder heat to be used over a shorter time and to concentrate the eluate for greater molar 
activity,71 however this increases the number of steps during the radiolabelling process. 
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Cooling and neutralisation of the radiolabelling reactions are also required for [68Ga]Ga-
NO2APBP and [68Ga]Ga-BPAMD. [68Ga]Ga-BPAMD also requires purification post-
reaction.31 THP-Pam on the other hand can be labelled in a single step at room temperature at 
neutral pH in 5 minutes. The THP chelator is selective for gallium(III) over other metals and 
the labelling is not affected by metallic impurities at the levels found in typical 68Ge/68Ga 
generator elutions.54,55 The efficient labelling of THP also allows for labelling at low 
concentrations and obviates the need for concentration of the generator eluate prior to 
labelling.49 
 
Table 1: Radiolabelling of the tracers evaluated in this study 
Radiotracer Radiolabelling conditions Other processing for in vivo use 
[68Ga]Ga-THP-Pam 
Radionuclide: 68Ge/68Ga generator  
Reaction conditions: 5 min, room 
temperature, pH 7 
- None. 
[68Ga]Ga-BPAMD 
Radionuclide: 68Ge/68Ga generator  
Reaction conditions: 15 min, 
95°C, pH 4 
- Post-processing of 68Ge/68Ga generator 
eluate prior to radiolabelling.*  
- Cooling. 
- Cation exchange column. 
- Neutralisation of reaction. 
[68Ga]Ga-NO2APBP 
Radionuclide: 68Ge/68Ga generator  
Reaction conditions: 10 min, 
95°C, pH 4 
- Post-processing of 68Ge/68Ga generator 
eluate prior to radiolabelling.* 
- Cooling. 
- Neutralisation of reaction. 
[18F]NaF Cyclotron production - 2 ion exchange columns. 
* Not essential; allows milder radiolabelling conditions and high molar activities 
 
 
In vitro stability. To evaluate the stability of [68Ga]Ga-THP-Pam towards transchelation to 
plasma proteins, it was incubated in human serum at 37°C for 3 h and the transchelation of 68Ga 
monitored by size-exclusion HPLC. This was monitored for 180 min, which was judged sufficient due 
to the short half-life of 68Ga and fast pharmacokinetics commonly found with BPs (and hence imaging 
patients no later than 3 h post-injection). In this timeframe, no transchelation of 68Ga from [68Ga]Ga-
THP-Pam was observed and the complex remained intact and chemically unmodified. To further 
evaluate the stability of [68Ga]Ga-THP-Pam, it was incubated in 1 mM EDTA solution in PBS 
(>1000-fold excess EDTA) at 37°C for 3 h. After 3 h, the stability of [68Ga]Ga-THP-Pam was 
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98.7 ± 1.2 %. (Figure S1). These results indicate not only the radiochemical stability of the 
[68Ga]Ga-THP-Pam complex, but also the stability of the thiourea bonds between the chelator 
and the BP under these conditions. 
In comparison, Fellner et al. reported [68Ga]Ga-BPAMD showed 4.2 ± 0.8% 
degradation over this timescale in PBS at 37°C.31 Serum stability has not been reported for 
[68Ga]Ga-NO2APBP, but previous in vivo data both for small animals and humans demonstrated 
high stability for [68Ga]Ga-BPAMD and [68Ga]Ga-NO2APBP.5,26-28,31-33 In support of this, the 
in vivo data reported here with [68Ga]Ga-NO2APBP (vide infra) are in agreement with in vivo 
stability for this radiotracer. 
In vitro calcium mineral binding. To assess the affinity and selectivity of different 68Ga-BPs 
and [18F]NaF towards several calcium minerals that are relevant to human disease, an in vitro 
binding assay was performed. The binding of [68Ga]Ga-THP-Pam, [68Ga]Ga-BPAMD, 
[68Ga]Ga-NO2APBP and [18F]NaF to a range of calcium salts was compared, including blocking 
studies in which the calcium salts were preincubated with an excess of relevant blocking agents 
(non-radioactive fluoride or bisphosphonate) (Figure 5). All the tested agents showed high 
binding to HAp (mean binding values in the range 78–93 %) which could be blocked (mean 
values in the range 1–6 %). [68Ga]THP-Pam exhibited specific binding to all the tested salts, 
with the lowest value being the binding to calcium oxalate (mean value 31%). [68Ga]Ga-
NO2APBP generally exhibited the highest binding across the salts tested but with different 
trends to [68Ga]Ga-THP-Pam, showing lower binding to calcium pyrophosphate (mean binding 
values of 45% vs. 60%) but higher binding to calcium oxalate (mean binding 60%). [68Ga]Ga-
BPAMD generally showed the lowest binding of the 68Ga-BPs, although it bound more to HAp 
than [68Ga]Ga-THP-Pam (mean binding 87% vs. 78%), but lower than [68Ga]Ga-NO2APBP 
(mean binding 93%) and showed similar calcium pyrophosphate binding (mean binding 60%) 
to that of [68Ga]Ga-THP-Pam. Contrary to expectation, the blocking experiments of [18F]NaF 
with calcium carbonate, calcium phosphate and calcium oxalate showed higher binding than 
the non-blocking experiments. The reason for this is unknown and may be due to the formation 
of an intermediate partially fluoridated salt due to the presence of higher concentrations of 
sodium fluoride in the blocking study, which can more readily bind [18F]F- than the original 
salt, although this hypothesis remains untested. Overall, it was found that 68Ga-BPs and 
[18F]NaF have high binding affinity towards HAp (mean binding of 68Ga-BPs = 85.8 ± 4.3%, 
[18F]NaF = 88.4 ± 4.6%), which could be blocked by using excess unlabelled BP or fluoride, 
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respectively (mean blocked binding of 68Ga-BPs = 2.6 ± 1.6%, [18F]NaF = 2.2 ± 0.2%). For 
non-HAp calcium minerals, however, only 68Ga-BPs showed significant binding (mean 
binding of 68Ga-BPs across non-HAp minerals = 51.7 ± 18.0%) whereas binding of [18F]NaF 
was negligible (mean binding of [18F]NaF across non-HAp minerals = 8.4 ± 4.6%). Thus, these 
results are in agreement with the binding mechanisms outlined in Scheme 1, whereby BPs are 
able to bind to calcium ions on the surface of all these minerals. In the case of HAp, the only 
mineral with available hydroxyl groups within its lattice, [18F]F- substitution results in binding 
to the salt.12 This confers HAp selectivity to [18F]NaF. However, affinity to other calcium 
minerals may be advantageous in imaging ectopic or pathological calcification as previously 
discussed. In this regard, BP-based tracers may be of interest, in addition to their cyclotron-
independent availability, in the imaging of vascular calcification in comparison to [18F]NaF. 
The targeting of different calcium materials may also mean that combining 68Ga-BPs and 
[18F]NaF could provide complementary information which may be diagnostically useful in 
identifying non-HAp calcified deposits. 
 16 
 
Figure 5. Binding of each radiotracer to an array of calcium salts in saline and room temperature. (A) [68Ga]Ga-
THP-Pam binding, blocking with pamidronate. (B) [68Ga]Ga-BPAMD binding, blocking with alendronate. (C) 
[68Ga]Ga-NO2APBP binding, blocking with pamidronate. (D) [18F]NaF binding, blocking with sodium fluoride. 
(E) Comparison of the mean binding to HAp of 68Ga-BPs and [18F]NaF. (F) Comparison of the mean binding to 
non-HAp calcium salts of 68Ga-BPs and [18F]NaF. HAp = hydroxyapatite; CC = calcium carbonate; CP = calcium 
phosphate dibasic; CPy = calcium pyrophosphate; β-TCP = β-tricalcium phosphate; CO = calcium oxalate 
monohydrate. 
 
In vivo evaluation. To evaluate the in vivo pharmacokinetics (PK), biodistribution, and 
calcium mineral capabilities of these radiotracers, we compared [68Ga]Ga-THP-Pam with 
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[68Ga]NO2APBP and [18F]NaF in an in vivo PET imaging study in 6–8 weeks old healthy 
immunocompetent mice. This is a good model for the in vivo evaluation of calcium mineral-
seeking radiotracers as young mice have metabolically active growing bones. It is worth noting 
that [68Ga]Ga-NO2APBP has previously been tested in patients, including a direct comparison 
to both [18F]NaF and [99mTc]Tc-MDP.5,28 Thus, it is a leading candidate for gallium-68 labelled 
BPs, and hence it was chosen as a BP standard against which [68Ga]Ga-THP-Pam could be 
compared. [18F]NaF, due to the widespread use and its comparable results to [68Ga]Ga-
NO2APBP in patients with bone metastases,5 was also included in our comparative in vivo 
study. 
The in vivo PET-CT imaging results are shown in Figures 6 and 7. All radiotracers were 
injected intravenously and imaged dynamically for 60 min, showing fast PK profiles and high 
binding to bone, as expected. The main differences were related to kidney clearance and 
excretion. Both 68Ga-BPs showed fast renal excretion, but [68Ga]Ga-NO2APBP cleared faster 
from the kidneys than [68Ga]Ga-THP-Pam, as demonstrated in Figure 7 by the visible kidney 
uptake at 40–59 min for [68Ga]Ga-THP-Pam, which was barely visible after 20–40 min in the 
case of [68Ga]Ga-NO2APBP. Interestingly, we found a lack of renal clearance with [18F]NaF 
(Figure 6A). This was surprising as [18F]NaF renal clearance/bladder accumulation is 
commonly observed in rodent studies, as well as in human clinical PET scans.5,33 We believe 
this to be an experimental artefact due to the use of isoflurane anaesthesia, but this hypothesis 
was not evaluated further. PK data were generated from regions of interest (ROI) within the 
PET images to calculate the fractions of injected dose per volume (mL) of tissue (Figure 6A). 
Using the knees as areas with known metabolically active new bone formation, the ROI image-
analysis data showed a similar level of binding for both [68Ga]Ga-THP-Pam (14.9 ± 1.0 %ID 
mL-1 at 60 min) and [68Ga]Ga-NO2APBP (15.7 ± 2.1 %ID mL-1 at 60 min) (Figure 6B). Each 
plateaued at approximately 20 minutes post-injection. In the case of the animals injected with 
[18F]NaF, knee uptake increased continuously 55 min post-injection, reaching 54.5 ± 5.1 % ID 
mL-1 after 1 h. This significantly higher knee binding of fluoride vs. BPs found may be 
attributable to the lack of excretion discussed above. To determine blood clearance, we used a 
ROI over the heart as a proxy and the data were fitted to a two-compartment PK model (Figure 
6C). All radiotracers showed a two-stage blood clearance with a remarkably similar fast first 
half life (t1/2(fast) = 1.33 ± 0.12 min; mean ± SD for all three radiotracers), followed by a slower 
clearance stage (t1/2(slow) <12 min for all tracers), with the fastest being [68Ga]Ga-NO2APBP 
(t1/2(slow) = 6.6 min). Accordingly, the area under the curve from 3–59 min (AUC3–59) for 
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[68Ga]Ga-NO2APBP (98.6 ± 3.4 %ID min mL-1) was lower than that of [68Ga]Ga-THP-Pam 
(126.4 ± 7.5 %ID min mL-1), and [18F]NaF (122.3 ± 5.1 %ID min mL-1). Thus, whilst both 
68Ga-BPs show comparable high bone uptake and fast PK profiles, [68Ga]Ga-NO2APBP shows 
slightly faster circulation/renal clearance compared to [68Ga]Ga-THP-Pam.  
 
Figure 6. Pharmacokinetic data for the three PET tracers evaluated in vivo (n = 4 for each tracer). (A) Activity 
(%ID/mL) over time (min) in selected organs of interest. (B) Tracer uptake in knee, used as a representative ROI 
of active bone. (C) Blood clearance fitted to two-compartment pharmacokinetic model using the heart as a 
representative ROI for blood. 
 
At the end of the imaging session mice were allowed to recover from anaesthesia for 1 
h to allow for further radiotracer clearance, and subsequently culled for ex vivo biodistribution 
studies using gamma-counting (Figure 8; values are tabulated in Table S4). Despite the time 
lag of one hour, the in vivo PET imaging analyses results were in agreement with the ex vivo 
biodistribution, with [68Ga]Ga-THP-Pam and [68Ga]Ga-NO2APBP showing similarly high 
femur uptake values (14.1 ± 3.7 %ID/g vs. 20.1 ± 5.2 % ID/g respectively; p = 0.101 ) and 
[18F]NaF having the highest of the three (47.1 ± 8.3 % ID/g) (Figure 8). [68Ga]Ga-THP-Pam 
showed higher accumulation in kidney and small intestines (p < 0.001), although these uptake 
values were very low (1.4–2.5 % ID/g). These levels of kidney uptake are unlikely to interfere 
with the imaging of bone metastases or vascular calcification but may be problematic for 
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imaging calcification in this organ. The bone-to-muscle ratios were similarly high (ca. 40) for 
all three radiotracers (Figure 8).  
 
 
 
Figure 7. PET-CT study showing representative maximum intensity projection (MIP) images of each 
radiotracer over three windows of time in healthy BALB/c mice. 
 20 
 
 
Figure 8. Ex vivo biodistribution of [68Ga]Ga-THP-Pam, [68Ga]Ga-NO2APBP and [18F]NaF 120 min post-
injection. Bone-to-muscle ratio inset. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. 
 
Conclusions 
[68Ga]Ga-THP-Pam, a new calcium-mineral targeted radiotracer has been synthesised, 
characterised and evaluated in vitro and in vivo. Using NMR studies, we demonstrate that 
gallium binds THP-Pam via the THP chelator, and not the bisphosphonate moiety. The THP 
chelator allows high specific activity 68Ga radiopharmaceuticals with high radiochemical 
purities (>95%) at room temperature and within minutes. These properties avoid the need for 
expensive/complicated instrumentation that is common in PET chemistry and allow simple and 
efficient kit-based radiosynthesis in any radiopharmacy. In vitro studies demonstrate that, in 
contrast to [18F]NaF which is selective to hydroxyapatite, 68Ga-bisphosphonates have high 
binding affinity to several calcium salts that are present in human calcified vessels, including 
hydroxyapatite, with the binding of [68Ga]Ga-THP-Pam generally found to be between those 
of [68Ga]Ga-BPAMD and [68Ga]Ga-NO2APBP. In vivo studies in healthy mice showed that 
both [68Ga]Ga-THP-Pam and [68Ga]Ga-NO2APBP (which has been succesfully evaluated in 
humans, in comparison with [18F]NaF) have a comparable high and rapid uptake in bone tissue, 
as well as fast blood clearance and urinary excretion. All these results highlight the potential 
of 68Ga-bisphosphonates as cyclotron-independent alternatives to [18F]NaF, as well as for the 
imaging of vascular calcification lesions. In addition, the fast, simple and efficient 
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radiochemistry required to synthesise [68Ga]Ga-THP-Pam makes this radiotracer an appealing 
candidate for clinical translation. 
 
Materials and Methods 
Nomenclature of radiochemical species has been written in accordance with the conventions 
outlined by Coenen et al.72 
Materials 
THP-NCS was obtained from CheMatech, France. All other reagents were purchased from 
commercial sources unless stated otherwise. NO2APBP was synthesised according to reference 
32. BPAMD was synthesised according to reference 58. Gallium-68 was eluted as [68Ga]GaCl3 
from an Eckert & Ziegler 68Ge/68Ga generator in ultra-pure HCl (5 mL, 0.1 M) manufactured 
to GMP requirements (ABX, Germany). [18F]NaF in H2O was purchased from Alliance 
Medical, U.K. 1H and 31P{1H} NMR data were acquired on a Bruker 400 MHz and analysed 
using MestReNova software. HPLC was performed on an Agilent 1260 Infinity instrument 
with UV spectroscopic detection at 254 nm and Lablogic Flow-Count detector with Bioscan 
Inc. B-FC-3200 photomultiplier tube detector and analysed using Laura software. The mobile 
phase used for analytical and semi-preparative reverse-phase HPLC was composed of A: water 
with 0.1% TFA and B: MeCN with 0.1% TFA. The mobile phase used for size-exclusion HPLC 
was PBS. LC/MS data were acquired on an Agilent 1200 Series Liquid Chromatograph with 
UV spectroscopic detection at 254 nm and same column details as in reverse-phase HPLC, 
interfaced with an Advion ExpressionL CMS mass spectrometer with electrospray ionisation 
source. The mobile phase used for LC/MS was composed of A: water with 0.1% formic acid; 
and B: MeCN with 0.1% formic acid. Cartridge purification was performed using Sep-Pak 
tC18 Long Cartridges with 900 mg sorbent per cartridge with a particle size of 37–55 μm. 
Radio instant thin layer chromatography (ITLC) was developed on Agilent Technologies glass 
microfibre chromatography paper impregnated with silicic acid and analysed using a Lablogic 
Flow-count TLC scanner and a BioScan B-FC-3200 PMT detector using Laura software. The 
ITLC mobile phase was composed of 0.175 M citric acid and 0.325 M trisodium citrate in 
water unless stated otherwise. Radioactive samples were measured using a Capintec CRC-25R 
or an LKB Wallac 1282 Compugamma CS for which data were collected using EdenTerm 
software. PET/CT images were acquired using a NanoPET/CT scanner (Mediso Ltd., 
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Budapest, Hungary), reconstructed using Nucline v.0.21 software and images were analysed 
using VivoQuant® software (version 3.5, InviCRO Inc.). The centrifuge used was a Hettich 
MIKRO 20. Lyophilisation was performed using an Edwards Freeze Dryer Modulyo. 
 
Synthesis of disodium pamidronate (Pam) 
3-aminopropionic acid (15 g, 0.168 mol) and phosphorous acid (20.7 g, 0.252 mol) were 
suspended in sulfolane (54 mL) and heated to 75°C for 30 min. The mixture was allowed to 
cool to 35°C and phosphorus trichloride (50 mL, 0.569 mol) was added gradually in aliquots. 
The solution was heated to 65°C for 3 h with stirring and white precipitate began to form. The 
suspension was cooled to 0°C and quenched by the slow addition of ice-cold water over 1 h to 
give a clear solution. The solution was heated to 100°C for 3 h and then cooled to room 
temperature. Pamidronic acid was precipitated by the addition of ethanol, followed by 
filtration. The pamidronic acid was suspended in water (100 mL) and aqueous sodium 
hydroxide (20% w/w) was added with stirring until pH 8 was reached. The mixture was stirred 
at room temperature for 4 h. The solvents were evaporated and the residue was recrystallized 
from water/ethanol to give pamidronate disodium dihydrate as a white powder (12.55 g, 39.8 
mmol, 24%). ESI-MS: [M + H]+ m/z = 235.0; calc. for C3H12NO7P2 = 235.0. 1H NMR (D2O, 
400 MHz): δ 3.00–2.90 (2H. t), 2.00–1.88 (2H, m). 31P NMR (D2O, 162 MHz): δ 17.28. HPLC: 
254 nm, tR = 1.7 min, >99% purity (HPLC method 2). Elemental analysis for disodium 
pamidronate + 2 H2O: C = 11.84, H = 4.37, N = 4.45; calc.: C = 11.44, H = 4.16, N = 4.45. 
 
Synthesis of THP-Pam 
Pamidronate (14.5 mg, 52 μmol) was dissolved in a mixture of chelex-treated water (200 μL) 
and triethylamine (21.2 μL, 15.4 mg, 0.15 mmol) and heated to 90°C. Separately, THP-NCS 
(5 mg, 5.2 μmol) was added to triethylamine (21.2 μL, 15.4 mg, 0.15 mmol) immediately 
followed by the addition of chelex-treated water (200 μL), and agitated to dissolve the THP-
NCS. As soon as the THP-NCS had completely dissolved, the THP-NCS solution was added 
to the pamidronate solution and stirred in a sealed vial at 90°C for 2 h. The crude mixture was 
loaded onto a pre-washed Sep-Pak tC18 cartridge and the excess pamidronate was eluted in 5 
mL water + 0.1% TFA. The product was eluted in 5 mL 50% water + 0.1% TFA/50% 
acetonitrile + 0.1% TFA and collected in 0.5 mL fractions. Fractions were analysed by LCMS 
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and the relevant fractions were combined and lyophilised to yield a white powder (4.40 mg, 
3.68 μmol, 71%). ESI-MS: [M + 2H]2+ m/z = 598.7; calc. for C48H69N11O17P2S2 = 598.7. 1H 
NMR (D2O, 400 MHz): δ 7.30–7.05 (4H. m), 6.30–6.20 (3H, m), 4.48 (7H, s), 3.85–3.60 (6H, 
m), 3.49 (10H, m), 2.43–2.35 (4H, s), 2.23 (11H, m), 2.17–2.09 (8H, m), 1.95–1.82 (6H, m). 
31P NMR (D2O, 162 MHz): δ 17.86. HPLC: 254 nm, tR = 10.4 min, >99% purity (HPLC method 
2). 
NMR studies of gallium binding 
THP-Pam gallium binding 
THP-Pam (2.25 mg, 1.88 μmol) was dissolved in D2O (600 μL), and sodium carbonate in D2O 
(1 M) was added to keep the pH in the range 9 and increase solubility of THP-Pam. 1H and 31P 
NMR spectra were recorded. Gallium nitrate in D2O (10 μL, 0.627 μmol, 62.7 mM) was added 
to the NMR tube and more sodium carbonate was added to maintain a pH of 9 with shaking 
for 5 min. NMR spectra were recorded. This process was repeated two more times until 1 
equivalent of gallium had been added.  
Pamidronate gallium binding 
Pam (3.05 mg, 10.9 μmol) was dissolved in D2O (600 μL), and sodium carbonate in D2O (1 
M) was added to keep the pH in the range 9 and increase solubility of THP-Pam. The 31P NMR 
spectrum was recorded. Gallium nitrate in D2O (43.67 μL, 2.75 μmol, 62.7 mM) was added to 
the NMR tube and more sodium carbonate was added to maintain a pH of 9, with shaking for 
5 min. The 31P NMR spectrum was recorded. This process was repeated three more times until 
1 equivalent of gallium had been added. 
 
Synthesis of [68Ga]Ga-THP-Pam 
A 1 mg mL-1 aqueous solution of THP-Pam in water was prepared. THP-Pam solution (5 μL, 
5 μg, 4.18 nmol) was added to [68Ga]GaCl3 (250 μL, 15–90 MBq). Sodium bicarbonate solution 
in water (26 μL, 1 M) was added immediately. The mixture was agitated and the pH was 
checked to ensure it was in the range 6.5–7.5. Radiochemical yield and purity were evaluated 
after 5 min by ITLC (unbound 68Ga Rf = 0.8–1; [68Ga]Ga-THP-Pam Rf = 0–0.3) and after 10 
min by HPLC, method 2 (unbound 68Ga tR = 1.9 min; [68Ga]Ga-THP-Pam tR = 10.8 min).  
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Synthesis of [68Ga]Ga-NO2APBP  
Gallum-68 (140–200 MBq) eluted from a generator was passed through a Phenomenex Strata-
X-C 33 μm SPE cartridge. The cartridge was washed with acetone/0.1 M hydrochloric acid 
(80:20 v/v, 5 mL) to remove trace metal impurities. The gallium-68 was recovered from the 
cartridge by washing slowly with acetone/0.05 M hydrochloric acid (98/2 v/v, 700 μL) and 
added to aqueous HEPES buffer (pH 4, 0.125 M, 400 μL). Aqueous 1 mg mL-1 NO2APBP (8.69 
μL, 8.69 μg, 17 nmol) was added to the gallium-68/HEPES solution followed by heating to 
95°C for 10 min with venting to allow the acetone to evaporate. After cooling, pH was adjusted 
to 7 by adding aqueous sodium hydroxide (~10 μL, 1 M). 
Determination of LogP and Log D7.4 values 
For logP measurement, aliquots of [68Ga]Ga-THP-Pam (10 μL, ~700 kBq) were added to vials 
containing a mixture of octanol pre-saturated with water (500 μL) and water pre-saturated with 
octanol (500 μL). The tubes were shaken for 3 min and the mixture was centrifuged for 5 min 
to separate the octanol and PBS phases. Aliquots (50 μL) of each phase were taken and 
transferred to separate vials for counting of radioactivity. For measurement of logD7.4 the same 
procedure was performed, using PBS in place of water. 
Serum stability 
Freshly filtered human serum (200 μL) was added to a tube containing normal saline (100 μL) 
followed by incubation at 37°C. [68Ga]Ga-THP-Pam (100 μL, ~7 MBq) was added. Size 
exclusion HPLC (using method 3 (Table S3) was run prior to incubation, and after 60 and 180 
min of incubation. Serum proteins eluted at 5.0–9.0 min. [68Ga]Ga-THP-Pam eluted at 11.0 
min. 
Stability to EDTA competition 
An aliquot of EDTA solution in PBS (950 μL, 1 mM) was incubated at 37°C. [68Ga]Ga-THP-
Pam (50 μL, ~20 MBq) was added to the EDTA solution and incubated with stirring. Samples 
were analysed by ITLC (mobile phase: 1 M ammonium acetate in 1:1 water/methanol) after 60 
min and 180 min. Controls were performed using [68Ga]GaCl3 neutralised according to the 
method used in the synthesis of [68Ga]Ga-THP-Pam, in the absence of the THP-Pam ligand. 
Unbound 68Ga Rf = 0–0.3; [68Ga]Ga-THP-Pam Rf = 0–0.3; [68Ga]Ga-EDTA Rf = 0.7–1. 
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Binding to calcium salts 
A suspension of HAp (1 mg) in saline (1 mL) was prepared. For the blocking study this was 
prepared in advance with pamidronate (27.9 mg, 100 μmol) and incubated overnight prior to 
reaction. Once the suspensions were prepared, an aliquot of the reaction mixture containing the 
radiotracer (10 μL, ~700 kBq) was added to the suspension and incubated at room temperature 
for 1 h with continuous shaking. The suspensions were centrifuged at 9677 g for 5 min and the 
supernatant was removed to a new tube and the activities of both fractions were measured. All 
the above steps were also repeated with other calcium salts (CC, CP dibasic, CPy, β-TCP, CO). 
These measurements were repeated for [68Ga]Ga-BPAMD (blocking with alendronate), 
[68Ga]Ga-NO2APBP (blocking with pamidronate) and [18F]NaF (blocking with sodium 
fluoride). 
PET-CT imaging 
Animal imaging studies were ethically reviewed and carried out in accordance with the 
Animals (Scientific Procedures) Act 1986 (ASPA) U.K. Home Office regulations governing 
animal experimentation. Each mouse (5 per tracer, of which 4 were imaged and 1 was used 
only for biodistribution studies, normal BALB/c, female, aged 6–8 weeks, 17–20 g body 
weight) was anaesthetised by inhalation of isoflurane (2–3% in oxygen), the tail vein was 
cannulated. Then the mouse was placed in a preclinical PET/CT scanner, where anaesthesia 
was maintained and the bed was heated to maintain normal body temperature. CT was 
performed followed by 1 hour PET acquisition (1:5 coincidence mode; 5-ns coincidence time 
window). After the first minute, the radiopharmaceutical (100 ± 15 μL, 2.2–16.2 MBq) was 
injected and the animal was scanned. At the end of the scan, the animal was removed and 
allowed to recover for a further hour and culled at 2 h post-injection for biodistribution studies. 
Organs were harvested, weighed and counted with a gamma counter along with standards 
prepared from injected material. Dynamic PET/CT images were reconstructed using Tera-
Tomo 3D reconstruction (400–600 keV energy window, 1–3 coincidence mode, 4 iterations 
and subsets) at a voxel size of (0.4 × 0.4 × 0.4) mm3 and corrected for attenuation, scatter and 
decay. The data were binned into 17 frames (1 × 1, 10 × 3, 5 × 5 and 1 × 4 min) for dynamic 
analysis. Regions of interest were drawn over the knees as an area of growing bone, heart as 
an indication of blood, kidneys, bladder and liver. 
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